The influence of MHC polymorphism on the selection of T-cell determinants of FMDV in cattle.
There is a quest for the development of a new generation of vaccines consisting of well-defined subunit antigens. For a number of practical reasons it is attractive to develop vaccines on the basis of synthetic peptides. However, their efficacy may be limited by genetic restrictions imposed on T-cell recognition via major histocompatibility complex (MHC) polymorphism, as shown by many studies using inbred animal species. To study the effect of MHC polymorphism in an outbred species, we selected four cattle homozygous for different A-DR-DQ haplotypes, and another four cattle which shared one haplotype in combination with a haplotype of one of the MHC homozygous animals. We analysed responses to synthetic peptides comprising defined T-cell epitopes of foot-and-mouth disease virus (FMDV) in this selected group of FMDV-vaccinated cattle. This analysis shows that even in outbred animals. MHC polymorphism influences the responses to synthetic peptides. Interestingly, one of the peptides, VP4[20-34], was recognized in association with at least four different MHC haplotypes. Fine specificity analysis of this peptide revealed subtle shifts in the core epitope recognized. All peptides that induced lymphocyte proliferation in vitro were found to induce a T-helper type-1 (Th1) type of response, irrespective of the MHC haplotype involved. Together, these data support the notion that individuals carrying distinct MHC types can be vaccinated successfully by vaccines that include only a limited number of peptides. In the design of a peptide vaccine against FMDV we suggest inclusion of the highly conserved VP4 sequence 20-34.
Van Lierop
M J
MJ
Department of Immunology, Faculty of Veterinary Medicine, University of Utrecht, The Netherlands.
Nilsson
P R
PR
Wagenaar
J P
JP
Van Noort
J M
JM
Campbell
J D
JD
Glass
E J
EJ
Joosten
I
I
Hensen
E J
EJ
D000595:Amino Acid Sequence; D000818:Animals; D005537:Aphthovirus / Q000276:immunology*; D002417:Cattle; D002455:Cell Division / Q000187:drug effects; D016207:Cytokines / Q000235:genetics; D000939:Epitopes / Q000276:immunology*; D005260:Female; D006239:Haplotypes; D006650:Histocompatibility Testing; D008285:Major Histocompatibility Complex / Q000235:genetics*; D008969:Molecular Sequence Data; D011110:Polymorphism, Genetic; D011994:Recombinant Proteins / Q000008:administration & dosage; D013601:T-Lymphocytes / Q000276:immunology*; D018417:Th1 Cells / Q000276:immunology; D014611:Vaccination; D014764:Viral Proteins / Q000276:immunology
D016207:Cytokines; D000939:Epitopes; D011994:Recombinant Proteins; D014764:Viral Proteins